...
首页> 外文期刊>Revista Brasileira de Colo-Proctologia : orgao oficial >The epidemiological profile of inflammatory bowel disease patients on biologic therapy at a public hospital in Alagoas
【24h】

The epidemiological profile of inflammatory bowel disease patients on biologic therapy at a public hospital in Alagoas

机译:在阿拉戈斯州一家公立医院接受生物治疗的炎症性肠病患者的流行病学概况

获取原文
           

摘要

Introduction: Inflammatory Bowel Diseases (IBD), represented by Crohn's disease (CD) and ulcerative colitis (UC) are chronic and idiopathic inflammatory conditions involving the gastrointestinal tract. There are several epidemiological studies that have shown an increased incidence of IBD worldwide. Objective: To analyze the epidemiological profile of patients with IBD under biologic therapy, treated in a coloproctology outpatient clinic, Hospital Universitario Professor Alberto Antunes, Alagoas. Methods: Retrospective observational clinical study, conducted by collecting patients' records and interviewing them at the time of follow-up. Results: 40 patients were evaluated: 70% female, 27 patients (67.5%) with CD and 13 (32.5%) with UC, mean age of 37.8 years and predominance of white ethnicity. The ileocolonic area was more frequently affected among patients with CD (33.3%), whereas the extensive colitis presentation predominated among UC patients (61.5%). 95% of the patients received some medication before using biologicals. 70% of the respondents remain in deep remission in the period of 6–60 months. Conclusion: The socioeconomic profile of patients was similar to that described in the literature. Crohn's disease was more frequent in our study, while extensive colitis was more common among UC patients. Most patients used biologicals after failure of other treatment options.
机译:简介:以克罗恩病(CD)和溃疡性结肠炎(UC)为代表的炎症性肠病(IBD)是涉及胃肠道的慢性和特发性炎症。几项流行病学研究表明,全球IBD的发病率增加。目的:分析在阿拉戈斯大学大学教授阿尔贝托·安特内斯(Alberto Antunes)的一所妇产科门诊诊所接受生物疗法治疗的IBD患者的流行病学特征。方法:回顾性观察性临床研究,通过收集患者记录并在随访时进行访谈来进行。结果:对40例患者进行了评估:女性为70%,CD患者为27例(67.5%),UC患者为13例(32.5%),平均年龄为37.8岁,以白人为主。患有CD的患者回肠结肠区域受到影响的频率更高(33.3%),而在UC患者中以结肠炎广泛表现为主(61.5%)。 95%的患者在使用生物制剂之前已接受过一些药物治疗。 70%的受访者在6至60个月内仍处于深度缓解状态。结论:患者的社会经济特征与文献中描述的相似。在我们的研究中,克罗恩病更为常见,而广泛性结肠炎在UC患者中更为常见。大多数患者在其他治疗方案失败后使用了生物制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号